Skip to content
← Breast Cancer

FOR PATIENTS · SOURCE READING

Chemotherapy drugs used for breast cancer

Source: Chemotherapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

NCI patient treatment article for this disease Exact source article; not a clinically reviewed indication or current-standard recommendation.

Context: Chemotherapy for Breast Cancer

Chemotherapy drugs used for breast cancer

Chemotherapy drugs used to treat breast cancer include:

anthracyclines, such as doxorubicin, liposomal doxorubicin, and epirubicin

Source links and citations

capecitabine

Source links and citations

cyclophosphamide

Source links and citations

eribulin

Source links and citations

fluorouracil (5-FU)

Source links and citations

gemcitabine

Source links and citations

ixabepilone

Source links and citations

methotrexate

Source links and citations

platinum agents, such as cisplatin or carboplatin

Source links and citations

taxanes, such as paclitaxel, docetaxel, and albumin-bound paclitaxel

Source links and citations

Combinations of chemotherapy drugs may be used. Other chemotherapy drugs not listed here may also be used.

Chemotherapy may also be combined with other kinds of drugs. For example:

HER2-positive breast cancer may be treated with both chemotherapy and targeted therapy, such as trastuzumab and pertuzumab. Learn more about these drugs at Targeted Therapy for Breast Cancer.

Source links and citations

Triple-negative breast cancer may be treated with both chemotherapy and the immunotherapy drug pembrolizumab. Learn more about Triple-Negative Breast Cancer Treatment.

Source links and citations

Hormone receptor–positive breast cancer may be treated with both chemotherapy and hormone therapy. Learn more about Hormone Therapy for Breast Cancer.

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice